A Biocompatible Nanofibers‐Based Microchip for Isolation and Nondestructive Release of Fetal Nucleated Red Blood Cells

Sun, Yue; Li, Naiqi; Cai, Bo; Wei, Xiaoyun; Wang, Zixiang; Cui, Heng; Zhao, Dongshan; Zhang, Yuanzhen; Zhao, Xingzhong

doi:10.1002/admi.202001028

Cited by 7 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Separation Methods Based On Micro/nanotechnologiesmentioning

confidence: 99%

“…In vivo, nanomaterials can perform targeted transport of the coated drugs to the lesion, thus reducing immune rejection, and increasing the treatment efficacy of the drug. This technology has been widely used for cell sorting [ 154 , 155 ], liquid biopsy [ 156 ], fluorescent labeling [ 157 , 158 ], biosensors [ 159 , 160 ], and target drug delivery [ 161 , 162 ].…”

Section: Separation Methods Based On Micro/nanotechnologiesmentioning

confidence: 99%

“…Unfortunately, the release method affected the cell viability. To solve this problem, Sun et al [ 154 ] designed the chitosan nanostructured substrates based on electrospinning and combined with NHS-(S-S)-Biotin modified with anti-CD147 to achieve sorting as well as the undamaged release of fNRBCs (Fig. 3 d).…”

Section: Separation Methods Based On Micro/nanotechnologiesmentioning

confidence: 99%

“…These fNRBCs need to be released before the downstream identification of the fetal origin and clinical analysis. Common release methods include three major categories: (1) biochemical methods such as DTT [ 154 ], MMP-9 [ 14 ], oxalic acid solution [ 38 ], DNA hybridization [ 177 ]; (2) physical methods such as electrical stimulation [ 30 ], magnetic field stimulation [ 170 ], photo-stimulation [ 179 ]; (3) laser microdissection techniques [ 180 ]. Since highly specific antibody proteins for fNRBCs have not yet been found, three-immunofluorescence identification makes it difficult to distinguish nucleated erythrocytes from the fetus and mother.…”

Section: Clinical Applications Of Fnrbcsmentioning

confidence: 99%

See 3 more Smart Citations

Noninvasive prenatal diagnosis targeting fetal nucleated red blood cells

Chen

Sutlive

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Noninvasive prenatal diagnosis (NIPD) aims to detect fetal-related genetic disorders before birth by detecting markers in the peripheral blood of pregnant women, holding the potential in reducing the risk of fetal birth defects. Fetal-nucleated red blood cells (fNRBCs) can be used as biomarkers for NIPD, given their remarkable nature of carrying the entire genetic information of the fetus. Here, we review recent advances in NIPD technologies based on the isolation and analysis of fNRBCs. Conventional cell separation methods rely primarily on physical properties and surface antigens of fNRBCs, such as density gradient centrifugation, fluorescence-activated cell sorting, and magnetic-activated cell sorting. Due to the limitations of sensitivity and purity in Conventional methods, separation techniques based on micro-/nanomaterials have been developed as novel methods for isolating and enriching fNRBCs. We also discuss emerging methods based on microfluidic chips and nanostructured substrates for static and dynamic isolation of fNRBCs. Additionally, we introduce the identification techniques of fNRBCs and address the potential clinical diagnostic values of fNRBCs. Finally, we highlight the challenges and the future directions of fNRBCs as treatment guidelines in NIPD. Graphical Abstract

show abstract

Section: Separation Methods Based On Micro/nanotechnologiesmentioning

confidence: 99%

Section: Separation Methods Based On Micro/nanotechnologiesmentioning

confidence: 99%

Section: Separation Methods Based On Micro/nanotechnologiesmentioning

confidence: 99%

Section: Clinical Applications Of Fnrbcsmentioning

confidence: 99%

See 2 more Smart Citations

Noninvasive prenatal diagnosis targeting fetal nucleated red blood cells

Chen

Sutlive

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…The fNRBCs are a promising cell type for noninvasive prenatal testing with a short lifespan (25–35 day half-life in adult circulation), preventing contamination from previous pregnancies. fNRBCs are abundant in fetal blood early in gestation, , but they are rare in maternal peripheral blood with a reported occurrence ranging from 3 to 26 cells per mL. − They have been successfully enriched from maternal blood by MACS, FACS, and microfluidics techniques …”

mentioning

confidence: 99%

Sequential Ensemble-Decision Aliquot Ranking Isolation and Fluorescence In Situ Hybridization Identification of Rare Cells from Blood by Using Concentrated Peripheral Blood Mononuclear Cells

Qin

et al. 2021

Anal. Chem.

View full text Add to dashboard Cite

Isolation and analysis of circulating rare cells is a promising approach for early detection of cancer and other diseases and for prenatal diagnosis. Isolation of rare cells is usually difficult due to their heterogeneity as well as their low abundance in peripheral blood. We previously reported a two-stage ensemble-decision aliquot ranking platform (S-eDAR) for isolating circulating tumor cells from whole blood with high throughput, high recovery rate (>90%), and good purity (>70%), allowing detection of low surface antigen-expressing cancer cells linked to metastasis. However, due to the scarcity of these cells, large sample volumes and large quantities of antibodies were required to isolate sufficient cells for downstream analysis. Here, we drastically increased the number of nucleated cells analyzed by first concentrating peripheral blood mononuclear cells (PBMCs) from whole blood by density gradient centrifugation. The S-eDAR platform was capable of isolating rare cells from concentrated PBMCs (108/mL, equivalent to processing ∼20 mL of whole blood in the 1 mL sample volume used by our instrument) at a high recovery rate (>85%). We then applied the S-eDAR platform for isolating rare fetal nucleated red blood cells (fNRBCs) from concentrated PBMCs spiked with umbilical cord blood cells and confirmed fNRBC recovery by immunostaining and fluorescence in situ hybridization, demonstrating the potential of the S-eDAR system for isolating rare fetal cells from maternal PBMCs to improve noninvasive prenatal diagnosis.

show abstract

Electrochemical Deposited Calcium Phosphate Nanomaterials with Micro‐Nano Interface for Capture and Non‐Invasive Release of Cancer Cells

Zhang

et al. 2021

Adv Materials Inter

Self Cite

View full text Add to dashboard Cite

CTCs), which escape from primary tumor and invade into patient peripheral blood circulation system, take major responsibility in cancer metastasis. [2] CTCs contain plenty of information about the primary tumor and the variety of protein molecules at different cancer stage which will help researchers to comprehensively understand and assist to offer more detailed therapeutic schedule. [3] Therefore, CTCs have been regarded as tumor biomarkers and a real-time "liquid biopsy" signal in solid tumors. [4] Isolating CTCs from cancer patients' blood was the first step to research CTCs, which attracted huge attention because the number of CTCs was just one per hundred million of normal blood cells, where large amount of red blood cells and leukocytes exist in primary tumor. [5] It is a challenge to separate the CTCs from normal blood cells and maintain the cells' activity for a follow-up study. Currently, kinds of platforms have been developed for capturing CTCs, including different materials, such as nanoparticles, [6] nanowires, [7] nanotubes, [8] and different methods, such as magnetic separation, [9] flow cytometry, [10] cell size, [11] density gradient sedimentation, [12] and surface electrochemical property. [13] Different micro-structures integrated in microfluidic chips were used to capture and purify CTCs, [14] and enrich heterogeneous CTCs subpopulation. [15] Aptamer had been used widely for modification and precisely recognize target cancer cells. [16] But those methods have their inherent insufficiency, for example, immuno-magnetic bead capture has a weak basis of releasing target cells from magnetic makings, ferromagnetic compounds can shield reflected color of other stuff. Hence it is vital to control the concentration of immunomagnetic bead for further observation in fluorescence analysis. Different levels of damage are caused on cellular film in electrochemical collection where voltage is applied. The prior modification of microfluidic chips is time-consuming and complex, and skillful researcher is needed when applied in clinical test.The size and specific antigen of CTCs are utilized to separate and capture CTCs from patient peripheral blood samples. In addition, the microenvironments of CTCs are also utilized to identify CTCs from normal blood cells. It is reported that the pH range of tumor tissue is 6.2-6.9, which is lower than that in normal organs (7.3-7.4). CTCs and normal cells are dispersed A low cost and easily fabricated 3D micro-nano biocompatible calcium phosphate (CaP) microstructure platform is developed to efficiently capture and non-destructively release cancer cells. The thickness of CaP is ≈3 µm after 2.5 min deposition and increased to ≈12 µm after 10 min deposition. The void size between CaP nanosheets is increased when the electro deposition time is increased. This micro-nano bio-interface is suitable for cancer cell capturing and culturing. More than 90% for the EpCAM positive cells are captured on the CaP substrates where the specific anti-EpCAM antibody is modified. On th...

show abstract

A Biocompatible Nanofibers‐Based Microchip for Isolation and Nondestructive Release of Fetal Nucleated Red Blood Cells

Cited by 7 publications

References 48 publications

Noninvasive prenatal diagnosis targeting fetal nucleated red blood cells

Noninvasive prenatal diagnosis targeting fetal nucleated red blood cells

Sequential Ensemble-Decision Aliquot Ranking Isolation and Fluorescence In Situ Hybridization Identification of Rare Cells from Blood by Using Concentrated Peripheral Blood Mononuclear Cells

Electrochemical Deposited Calcium Phosphate Nanomaterials with Micro‐Nano Interface for Capture and Non‐Invasive Release of Cancer Cells

Contact Info

Product

Resources

About